<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20080904001199N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-10-05</date_registration>
      <primary_sponsor>Darudarman Salafchegan Co. (Knowledge-based)</primary_sponsor>
      <public_title>Dermaheal Effect on Diabetic Foot Ulcer</public_title>
      <acronym>SDWHE</acronym>
      <scientific_title>Evaluation of Dermaheal Ointment Healing Effects on Diabetic Foot Ulcer: Double-Blind Randomized Clinical Trial Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51263</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: No, Randomization description: The first step in the random process is to create a random sequence. The second step after creating a random sequence is to hide the generated sequence. To use the random number table, we must first determine the number of the table to read. The second is to consider numbers for different groups (for example, pair numbers for intervention A and individual numbers for intervention B, then hand over one of the numbers and move in one of the directions predetermined and record the numbers We assign to different groups. Blocking is usually used to create a balance in the number of specimens assigned to each of the groups studied, for example, in blocks of 4 that have two allocations to the intervention group and two allocations to the control group Is taken, Blinding description: Given the fact that the treatments are prescribed as unprinted tubes, also the appearance of both ointments is similar in both control and intervention groups, the patient will not be informed about her/his assignment to the control or intervention group. Forasmuch as groups will be marked by letters A and B; and patient assignment to either A or B groups will be done using block randomization, therefore, the treating and wound assessor physician will not be informed of the patient's group assignment when examining the wound using a checklist. This will reduce the observation bias (data collection) which arises from mental presupposition. The second principal researcher will also be unaware of the grouping details. Finally, the statistician will statistically analyze the data without knowing the treatment assigned to group A or B. The First Principal researcher is not blinded and can reopen the codes and be informed about the received treatments of each patient (if necessary or and at the end of the study).</study_design>
      <phase>3</phase>
      <hc_freetext>Diabetic Foot Ulcer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Dermaheal Ointment                                                       In the form of ready-to-use tubes without printing. The wound and surrounding tissues will be cleansed with saline solution and dried with sterile gauze. Then, the dermaheal ointment will be applied to the wound using an abaisse-langue and, fixed by the anti-allergic adhesive &amp; a four-layer sterile dry gauze. Changing the dressing and applying the ointment should be done once a day for 4 weeks. Darmaheal ointment is a dressing based on herbal and natural products including Arnebia euchroma, thymes, Maticaria chamomilla L., Curcuma longa, wax, honey, and olive oil, which is produced by Darudarman Salafchegan Knowledge-Based Co. Intervention 2: Placebo group                                                                                                   In the form of ready-to-use tubes without printing. The wound and surrounding tissues will be cleansed with saline solution and dried with sterile gauze. Then, the placebo dressing will be applied to the wound using an abaisse-langue and, fixed by the anti-allergic adhesive &amp; a four-layer sterile dry gauze. Changing the dressing and applying the ointment should be done once a day for 4 weeks. Placebo dressing contains the inert substance Eucerin, which is produced by Darudarman Salafchegan Knowledge-Based Co.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is ethical</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Reza Amini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr. Shariati Hospital 5th floor</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411413137</zip>
        <telephone>+98 21 8822 0037</telephone>
        <email>mramini@tums.ac.ir</email>
        <affiliation>Endocrinology and Metabolism Research Institute</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Reza Mohajeri Tehrani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr. shariati Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411413137</zip>
        <telephone>+98 21 8822 0037</telephone>
        <email>mrmohajeri@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Wagner G 1&amp;2 Diabetic Foot Ulcer
Neuropathic and Neuroischemin Ulcer 0.7 ≤ ABI ≤ 1.2</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patient Disagreement to Participate
Use of Medications that can Interfere with Wound Healing such as Corticosteroids, Immunosuppressive agents, and Cytotoxic agents</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus with neurological complications</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Dermaheal Ointment                                                       In the form of ready-to-use tubes without printing. The wound and surrounding tissues will be cleansed with saline solution and dried with sterile gauze. Then, the dermaheal ointment will be applied to the wound using an abaisse-langue and, fixed by the anti-allergic adhesive &amp; a four-layer sterile dry gauze. Changing the dressing and applying the ointment should be done once a day for 4 weeks. Darmaheal ointment is a dressing based on herbal and natural products including Arnebia euchroma, thymes, Maticaria chamomilla L., Curcuma longa, wax, honey, and olive oil, which is produced by Darudarman Salafchegan Knowledge-Based Co.</i_keyword>
      <i_keyword>Placebo group                                                                                                   In the form of ready-to-use tubes without printing. The wound and surrounding tissues will be cleansed with saline solution and dried with sterile gauze. Then, the placebo dressing will be applied to the wound using an abaisse-langue and, fixed by the anti-allergic adhesive &amp; a four-layer sterile dry gauze. Changing the dressing and applying the ointment should be done once a day for 4 weeks. Placebo dressing contains the inert substance Eucerin, which is produced by Darudarman Salafchegan Knowledge-Based Co.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Ulcer Area. Timepoint: End of every week. Method of measurement: Images &amp; and ruler.</prim_outcome>
      <prim_outcome>Wound Discharge. Timepoint: End of every week. Method of measurement: Color, odor and amount by wound healing checklist.</prim_outcome>
      <prim_outcome>Surrounding tissues. Timepoint: End of every week. Method of measurement: Color, hotness, edema and sense by wound healing checklist.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>ABI. Timepoint: End of treatment. Method of measurement: ABI measurement Device.</sec_outcome>
      <sec_outcome>FBS. Timepoint: End of treatment. Method of measurement: Glucometer.</sec_outcome>
      <sec_outcome>Pain severity. Timepoint: End of every week. Method of measurement: Visual pain scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Darudarman Salafchegan Co. (Knowledge-based)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-09-23</approval_date>
        <contact_name>Institutional Research committee Endocrine &amp; Metabolism Research Institute - Tehran University of Me</contact_name>
        <contact_address>NO 10, Jalal-AL-Ahmad St., Chmaran HWY., Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
